Accumulating evidence has revealed that BER exerts potential pro-apoptotic effects by modulating BAX/BCL2 (pro-/anti-apoptotic) expression in multiple cancers, including breast, lung, liver, gastric, colorectal, pancreatic, and ovarian cancers [12,60,69,70,71,72,73,74]. The gene discussed is BCL2; the disease is ovarian carcinoma.